Media
News & Events
Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer
Asceneuron appoints Dr. Thomas C. Wessel as Chief Medical Officer
Asceneuron initiates neuroimaging trial for ASN120290
Asceneuron initiates neuroimaging trial for tau modifier ASN120290
Asceneuron panelist at BIO-Europe 2018
Asceneuron will take part to a panel discussion at BIO-Europe, on November 5th-7th, 2018 in Copenhagen, Denmark.
ASN120290 receives Orphan Drug Designation from the FDA
Asceneuron’s tau modifier ASN120290 receives Orphan Drug Designation for progressive supranuclear palsy from the FDA
Asceneuron to present at the European Life Sciences CEO Forum
Our CEO Dirk Beher will be presenter and panellist at the 11th Annual European Life Sciences CEO Forum & Exhibition, February 26th-27th 2018, in Zurich.
Asceneuron to attend the 36th Annual J.P. Morgan Healthcare Conference
Asceneuron to attend the 36th Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2018 at the Westin St. Francis in San Francisco, CA.
Asceneuron to present at Neurotech Investing and Partnering Conference
Our CEO Dirk Beher will be presenter and panellist at Neurotech Investing and Partnering Conference, October 3rd 2017, in Geneva.
"Treating Tau: Finally, Clinical Candidates Are Stepping into the Ring"
Read a detailed conference report on our clinical tau modifier presented at AD/PD 2017
Asceneuron Receives Approval for Phase I Study of Oral Tau Inhibitor
Asceneuron Receives Regulatory Approval for Phase I Healthy Volunteer Study of Oral Tau Inhibitor
First-in-human trial of novel inhibitor targeting accumulation of toxic neurofibrillary tau tangles to fight neurodegenerative diseases including dementia
Asceneuron to participate in the 1st EuroTauMeeting
Asceneuron to participate in the 1st EuroTauMeeting or how to know everything about Tau protein and associated diseases in Lille, France, on April 27-28, 2017.